Lack of efficacy represented the largest single cause of treatment discontinuation, followed by adverse events. Similar dropoff rates were observed for RA patients within the Swiss Clinical Quality Management RA cohort receiving etanercept, infliximab, and adalimumab 3. These observations indicate a need to optimize the use of anti-TNF therapies in the treatment of immune-mediated inflammatory diseases (IMID). Some patients taking these agents may ultimately develop toxicities such as infection, autoimmunity, demyelinating disease, and malignancy. However, it has been documented that patients who initially respond to an anti-TNF agent and subsequently lose their response (secondary nonresponders) tend to achieve better response rates receiving a second anti-TNF agent than those who do not respond at all to initial anti-TNF treatment (primary nonresponders). In addition, there is evidence that switching from one TNF inhibitor due to lack of efficacy does not preclude successful treatment with a secondary TNF inhibitor. Several predictors of response have been identified, which may aid physicians in identifying those patients who will most benefit from anti-TNF therapy. Issues such as patient compliance, immunogenicity, and possibly involvement of cytokines aside from TNF contribute to the high dropoff rates for inefficacy. High dropoff rates have been observed not only in clinical trials but also in clinical practice, including a significant number of patients (~20%–30%) who do not initially respond to therapy 1. Dropoff rates, patients’ lack of response, and toxicity are issues that need to be addressed to render these therapies more effective for more patients.Īlthough many patients benefit from anti-tumor necrosis factor (TNF) therapy, there are significant numbers of patients who discontinue their use because of lack or loss of response, let alone side effects. However, the use of anti-TNF therapies still needs to be optimized. Stephen Thomas Erlewine of AllMusic called it the "culmination of all the musical directions The Cure were pursuing over the course of the '80s".The introduction of anti-tumor necrosis factor (TNF) therapies has dramatically improved the treatment of immune-mediated inflammatory diseases and provides treatment options for patients who do not respond to conventional disease-modifying antirheumatic drugs. It was greeted with a warm critical reception before later being acclaimed, eventually being placed at number 326 on Rolling Stone magazine's list of the " 500 Greatest Albums of All Time".
It remains The Cure's highest selling record to date, with more than three million copies sold worldwide. During production, founding member Lol Tolhurst was fired from the band.ĭisintegration became the band's commercial peak, charting at number three in the United Kingdom and at number twelve in the United States, and producing several hit singles including " Lovesong", which peaked at number two on the Billboard Hot 100. The Cure recorded Disintegration at Hookend Recording Studios in Checkendon, Oxfordshire, with co-producer David M. This, coupled with a distaste for the group's newfound popularity, caused Smith to lapse back into the use of hallucinogenic drugs, the effects of which had a strong influence on the production of the album. As he neared the age of thirty, vocalist and guitarist Robert Smith had felt an increased pressure to follow up on the group's pop successes with a more enduring work. The record marks a return to the introspective and gloomy gothic rock style the band had established in the early 1980s. Made in EU.ĭisintegration is the eighth studio album by British alternative rock band The Cure, released on by Fiction Records. Sealed - Brand new 180 gram 2LP remastered vinyl with gatefold cover.
0 kommentar(er)
